Two major cardiovascular updates presented at late‑stage meetings signal changes in LDL management. Merck reported Phase 3 data showing its oral PCSK9 inhibitor reduced LDL by up to 60% and halved LDL in two‑thirds of participants in a 2,900‑patient trial of people on statins. The oral, once‑daily candidate Enlicitide aims to deliver PCSK9‑level LDL cuts without injections. Separately, Amgen’s Repatha (evolocumab) demonstrated a 25% reduction in cardiovascular events when added to standard therapy in high‑risk patients who had never had a heart attack or stroke; first heart attacks were reduced by 36%, according to VESALIUS‑CV data presented at the American Heart Association. The two results together outline a potential near‑term expansion of options: an oral PCSK9 that could compete with monoclonal antibodies and strong outcomes data reinforcing PCSK9 inhibitors’ role in primary prevention.